BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20454926)

  • 1. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
    Seruga B; Amir E
    Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
    Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
    Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
    Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
    J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
    Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
    Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
    Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
    Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
    Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
    Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
    Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
    Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
    Briest S; Stearns V
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Brauch H; Jordan VC
    Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy.
    Josefsson ML; Leinster SJ
    Breast; 2010 Apr; 19(2):76-83. PubMed ID: 20096578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.
    Kiyotani K; Mushiroda T; Hosono N; Tsunoda T; Kubo M; Aki F; Okazaki Y; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
    Pharmacogenet Genomics; 2010 Sep; 20(9):565-8. PubMed ID: 20574415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen.
    Ferraldeschi R; Howell SJ; Thompson AM; Newman WG
    J Clin Oncol; 2010 Oct; 28(29):e584-5; author reply e586. PubMed ID: 20823421
    [No Abstract]   [Full Text] [Related]  

  • 19. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
    Newman WG; Hadfield KD; Latif A; Roberts SA; Shenton A; McHague C; Lalloo F; Howell S; Evans DG
    Clin Cancer Res; 2008 Sep; 14(18):5913-8. PubMed ID: 18794105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.